Apigenin Improves Ovarian Dysfunction Induced by 4‐Vinylcyclohexene Diepoxide via the AKT/FOXO3a Pathway

ABSTRACT Perimenopausal syndrome is a significant issue that disturbs women's metabolism, mood and quality of life. Apigenin (4′,5,7‐trihydroxyflavone) is a natural flavonoid that exhibits antioxidant, anti‐inflammatory and anticancer effects. The present study aims to investigate the effect of apigenin on perimenopausal syndrome by combining bioinformatics analysis with in vivo experiments. The mouse model with perimenopausal syndrome was established using 4‐vinylcyclohexene diepoxide (VCD) treatment. Apigenin alleviated VCD‐induced disorder of estrous cycle and shrinkage of ovarian tissue. The reduction of anti‐Muller hormone and the increase of follicle stimulation hormone and luteinizing hormone triggered by VCD were reversed by apigenin in a dose‐dependent manner. Apigenin suppressed the VCD‐induced decrease of primordial, primary, secondary and antral follicle number in ovarian tissue. Oxidative stress in ovarian tissue was activated by VCD treatment through increasing the reactive oxygen species production. High concentration of apigenin significantly reversed the alteration induced by VCD. Apigenin alleviated VCD‐induced cell apoptosis through regulating Bax, Bcl‐2, cleaved PARP1 and caspase‐3. Furthermore, the phosphorylation of AKT and FOXO3a was inhibited by VCD and activated by apigenin in a dose‐dependent manner. Collectively, apigenin effectively mitigates the ovarian dysfunction through suppressing oxidative stress and apoptosis via the AKT/FOXO3a signaling pathway.